Equity Overview
Price & Market Data
Price: $4.60
Daily Change: -$0.35 / 7.61%
Daily Range: $4.47 - $5.58
Market Cap: $94,182,720
Daily Volume: 38,277
Performance Metrics
1 Week: -2.04%
1 Month: -19.40%
3 Months: -11.11%
6 Months: -80.52%
1 Year: -80.52%
YTD: -60.36%
Company Details
Employees: 4
Sector: Health technology
Industry: Biotechnology
Country:
Details
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.